NeoTherapeutics, Inc. has expanded its Neotrofin spinal cord injury trial to include Gaylord Hospital in Wallingford, Connecticut. Gaylord is the second site participating in the spinal cord injury trial. The 12-week open-label study of Neotrofin in patients with subacute, complete spinal injury began at Rancho Los Amigos Hospital in Los Angeles in March. Additional sites are expected to join the study over the next few months.

"We are looking forward to participating in this clinical research", said David Rosenblum, M.D., medical director of the Spinal Cord Injury Program at Gaylord. "It is an exciting time for research in spinal cord injury and we continue to be committed to supporting efforts to improve the life of people with spinal cord injury."

Patients will receive Neotrofin for 12 weeks, and will be evaluated at regular intervals. In addition to extensive assessments for tolerance and safety, the Standard Neurological Classification of Spinal Cord Injury (SNCSCI) manual motor exam score will be used as the primary evidence of preliminary efficacy.

Secondary efficacy measures include: American Spinal Injury Association (ASIA) impairment scale (ASIA-IS), Functional Independence Measure (FIM) and SNCSCI-sensory exam.

Currently, three patients are taking Neotrofin at Rancho Los Amigos. Neotrofin is being developed for the treatment of Alzheimer’s disease and other neurodegenerative diseases such as Parkinson’s disease and spinal cord injury.

- This article first appeared in the Gaylord Hospital Newsletter

• Previous: NSCIA CT Chapter Advocay Report: Work Incentives
• Next: Osteoporosis and Spinal cord injury )
• Back to Archives
• Send This Article to a Friend!